Genelux vs Lyell Immunopharma
GNLX and LYEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GNLX and LYEL compare
Lyell Immunopharma is the larger company, worth 3.7 times as much as Genelux ($335M against $90.5M).
Lyell Immunopharma scores higher on the StockData Score (6 against 5 for Genelux), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GNLX | LYEL |
|---|---|---|
| Size and price | ||
| Market cap | $90.5M | $335M |
| Share price | $2.00 | $13.67 |
| Change, 1 year | −62.4% | −19.3% |
| Change, 5 years | – | −92.7% |
| Beta (5Y) | 0.73 | 1.37 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 12407× |
| P/B | 5.6× | 1.4× (better) |
| FCF yield | −31.7% (better) | −40.0% |
| Growth | ||
| Revenue growth (TTM) | – | −55.0% |
| Revenue growth, 5Y average | – | −65.9% |
| Profitability | ||
| Operating margin | – | −949981% |
| Net margin | – | −920285% |
| FCF margin | – | −496189% |
| Return on equity | −178% | −93.3% (better) |
| Return on invested capital | – | −782% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.39 | 5.36 (better) |
| Altman Z-score | −14.83 | −7.05 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Buyback yield | −20.8% | – |
| Shareholder yield | −20.8% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 21.7% | 48.9% |
| Held by insiders | 7.7% | 45.0% |
| Insider net buying, 12 months | −$341K | $74.4M (better) |
| Short interest, % of float | 10.9% | 10.5% |
Go deeper
- GNLX stock overview
- GNLX income statement
- GNLX valuation and score
- LYEL stock overview
- LYEL income statement
- LYEL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.